Eli Lilly secures US patent for oligonucleotide delivery compounds targeting liver disease.
The filing
Eli Lilly and Company received a US grant on November 10, 2026 for novel compounds designed to deliver oligonucleotides to the liver. The invention centers on delivery moieties that enable these compounds to treat diseases of the liver, as described in the patent's abstract.
This filing’s full text wasn’t read for this issue, so its claims and the applicant’s background aren’t shown. Both are in the record, under Sources.